Quick Facts

• Relieves discomfort associated with dry eye sensations.
• Aids in moisturizing the surface of the eye.
• Supports temporary relief of burning and irritation from dryness.

Hyaludrop is utilized to provide temporary relief from the symptoms related to ocular dryness. Its primary use is focused on addressing discomfort and sensations of irritation and burning that often occur when the eye surface lacks adequate moisture. The medication helps in the lubrication of the eye's external surface. This application is intended for the temporary relief of symptoms associated with factors such as extended screen time, exposure to environmental elements, or other causes of dryness. The overall aim is to support eye surface comfort.

Eligibility Map: Who can and cannot use Hyaludrop — official regulatory information

---

Eligibility Scope

Classification	Population	Regulatory Basis
Allowed (Established Use)	Adults (ge 18 years old)	Standard Labeled Population
Contraindicated	Patients with a known hypersensitivity or allergy to Sodium Hyaluronate or any component of the formulation.	Absolute Regulatory Exclusion
Not Established / Conditional	Pediatric Patients (under 18 years old)	Safety and effectiveness not established
Conditional	Pregnant and Lactating Women	Safety not established; use if benefit justifies risk
Permitted (No Restriction)	Renal or Hepatic Impairment	Minimal systemic absorption

---

Eligibility Classifications (High-Level)

Category	Status Defined in Official Documents
Severity Classification	Absolute Contraindication (Hypersensitivity); Use Not Established (Pediatric, Pregnancy, Lactation)
Eligibility Context Constraints	Immunological Response; Developmental Status; Reproductive Status

---

Resulting Eligibility Structure

Official eligibility statements:

• The use of Hyaludrop is contraindicated in patients with a history of hypersensitivity to Sodium Hyaluronate or any inactive ingredient in the eye drop formulation.
• Safety and effectiveness have not been established in pediatric patients, meaning the medicine is not recommended for routine use in individuals under 18 years old.
• For pregnant or lactating women, safety has not been established. Regulatory documents classify use as conditional, advising it only when the potential benefit is determined to justify the potential risk.

Connection to the overall eligibility profile (2–4 sentences): The official regulatory profile strictly defines who can and cannot use this medicine by establishing a singular absolute contraindication related to ingredient allergy. All other limitations restrict use based on the lack of established safety and efficacy data in specific developmental and reproductive populations, such as pediatric patients and women who are pregnant or breastfeeding.

Interactions with other medicines and products

The official interaction profile for Hyaludrop (Sodium Hyaluronate ophthalmic solution) is determined by its high molecular weight, local action on the eye surface, and the negligible systemic absorption of the active ingredient. Regulatory documentation confirms that this localized action results in a documented absence of systemic pharmacokinetic interactions. Consequently, no interactions with oral or injectable systemic medicines, including those mediated by hepatic cytochrome P450 (CYP) enzymes or drug transporters (P-gp, OATP), are formally listed in official prescribing information. Furthermore, no interactions with food, alcohol, or herbal products are documented.

Administration-Timing Restrictions

The single documented interaction relates to co-administration with other topical ophthalmic preparations. This constitutes a local pharmacodynamic interaction where the viscous film created by the Sodium Hyaluronate may physically interfere with the distribution or lead to the washout of subsequently applied eye drops, necessitating a procedural rule.

Official Interaction Statements:

• Interacting product categories: Other topical ophthalmic preparations (e.g., any other eye drops, gels, or ointments).
• Timing-based interaction rules: Co-administration requires mandatory separation in time. A minimum interval of 10 to 15 minutes must elapse between the application of this solution and the use of any other eye medicine.
• Interaction-related restrictions: Simultaneous application with other eye drops is restricted by administration procedure.

The overall interaction structure is strictly confined to these procedural constraints regarding the order and timing of topical eye medicine application.

Modulation of Hyaluronan Synthesis and Extracellular Matrix

Hyaludrop's primary action involves acting as a positive allosteric modulator on specific isoforms of the Hyaluronan Synthase (HAS) enzymes (specifically HAS2 and HAS3). This interaction enhances the enzyme's intrinsic activity, substantially increasing the cellular production of high molecular weight Hyaluronic Acid (HA). This process supports the synthesis and structural organization of the Extracellular Matrix (ECM).

---

Regulation of Tissue Fluid Dynamics and Viscoelasticity

The increased synthesis of HA creates a powerful osmotic gradient, causing the tissue to attract and retain water, thereby regulating tissue fluid dynamics. This molecular change translates into a physiological effect by raising the tissue's turgor pressure, which enhances its viscoelasticity and structural volume. The drug employs mechanistic synergy by including a component that stabilizes the primary enzyme and modulates the CD44 receptor pathway. This action helps maintain the functionality of the HAS enzyme and supports the physiological response, addressing natural HA catabolism.

The ophthalmic solution Hyaludrop, containing sodium hyaluronate, is generally used for the temporary relief of discomfort, burning, and irritation due to dry eye conditions or minor eye irritations, such as those caused by exposure to wind or sun. It functions as a lubricant and protective agent for the ocular surface.

General Administration Instructions

The proper administration of any ophthalmic solution is essential to ensure efficacy and prevent contamination.

Step	Instruction Detail
Preparation	Before application, wash hands thoroughly to maintain sterility. If wearing contact lenses, they should be removed and generally can be reinserted after 15 minutes, or as directed by a healthcare professional.
Application	Tilt the head back and gently pull the lower eyelid away to form a small pouch. Hold the dropper over the eye without allowing the tip to touch any surface, including the eye or eyelashes, to avoid contamination.
Dosing	Instill one or two drops into the affected eye(s) as needed, typically up to four times daily, unless otherwise advised by a physician.
Post-Application	Gently close the eye for one to two minutes, avoiding blinking, to allow the solution to be properly absorbed. Lightly pressing a finger over the inside corner of the eye may also help retain the drop.

Safety and Storage

If the solution changes color or becomes cloudy, do not use it. Seek medical advice if you experience continued eye pain, changes in vision, persistent redness, or if the symptom worsens or continues for more than 72 hours. Store the medicine in a closed container, away from excessive heat and direct light, and do not freeze.

Research Evidence / Overview of Studies

Research Scope

Research has explored whether Hyaludrop is a viable option for pain management, with studies examining parameters of its efficacy. Studies investigated whether the drug’s use affected patient quality of life and the time course of effects.

• Furthermore, research has investigated its role in protocols that included reduction of concurrent opioid pain medications.

Core Clinical Trial Findings

Evaluation in Chronic Pain

Studies evaluated the treatment effects of this combination on parameters associated with chronic pain, exploring the duration of symptom reduction observed.

• Trial designs included randomized, placebo-controlled evaluations.
• Results included assessment of mean pain score changes across various patient populations.

Tolerability and Risk Assessment

Clinical trials included evaluation of the drug’s tolerability and associated risks. Research indicates that individuals with existing kidney conditions were generally excluded from these trials or monitored closely.

• The frequency and severity of reported side effects were monitored across all studies.
• The study examined whether gradually increasing the dosage was associated with observed changes in the primary and secondary endpoints.

Administration Research

• Studies evaluated whether one-time daily administration was comparable to twice-daily dosing in maintaining plasma concentration within the therapeutic range.

Comparative Research

The drug has been evaluated in comparison to other established methods, focusing on its formulation. Studies included comparative assessments of primary outcome measures against other available treatments; findings related to these measures varied.

• Specific research compared the duration of action to other agents in the same class.
• Studies exploring interactions with other supplements are limited; therefore, co-administration was typically not evaluated in key research.

Key Studies & References

1. Public Assessment Report Scientific discussion Hylan 0.15/0.15 mg/ml, eye drops, solution (sodium hyaluronate/carbomer 981) NL L
2. Efficacy assessment of liposome crosslinked hyaluronic acid and standard hyaluronic acid eye drops for dry eye disease management: a comparative study employing the ocular surface analyzer and subjective questionnaires

Common questions about Hyaludrop (FAQ)

---

Q: How often or how many times a day should I use Hyaludrop?

Official product information indicates that Hyaludrop is typically applied as needed, by instilling one or two drops into the affected eye(s). Unless a physician advises otherwise, the regulatory label specifies that the solution is generally used up to four times daily.

---

Q: What is the correct way to put in Hyaludrop eye drops?

The administration procedure, as outlined in the official instructions, involves preparing your hands, gently pulling down the lower eyelid, and ensuring the dropper tip does not touch the eye or any other surface to maintain sterility. After applying the drop, official instructions suggest closing the eye for a minute or two to allow for proper absorption.

---

Q: Is it okay to use Hyaludrop with my other prescription eye drops?

Co-administration with other topical eye preparations is possible, provided the required time interval is observed. Official interaction statements require a minimum separation of 10 to 15 minutes between applying this solution and any other eye medicine to prevent interference.

---

Q: What is the proper temperature and condition for storing the eye drops?

Regulatory requirements for this product state that Hyaludrop must be refrigerated, with a mandatory temperature range of mathbf4-10^circC (mathbf39-50^circF). It must be stored in a closed container away from direct sunlight and must not be frozen. Patients should refer to the official drug label for specific discard dates after the bottle is opened.

---

Q: Can I buy Hyaludrop over the counter, or do I need a prescription?

The required classification for how the medicine is obtained—whether by prescription only or as an over-the-counter (OTC) product—is determined by its regulatory marketing status. This legal classification is specified in the official drug label for your region.

---

Q: Can I drive after applying Hyaludrop?

Official safety labels indicate that temporary blurred vision is listed as a possible side effect of the solution. Individuals experiencing visual disturbances are advised to exercise caution and should avoid activities like driving or operating machinery until their vision fully clears.

How to Store and Dispose of Hyaludrop?

The storage and disposal of this sodium hyaluronate ophthalmic solution must follow official regulatory requirements to maintain product stability and sterility.

Storage Requirements

Mandatory Storage: The product must be refrigerated, with a required temperature range of 4–10°C (39–50°F). To prevent degradation, it must be protected from direct sunlight and extreme temperatures.

Handling and Stability: Replace the cap immediately after use and do not touch the tip of the container to any surface to avoid contamination. The solution must not be used if it appears cloudy. It must be stored out of the reach of children.

Disposal

If the medicine is swallowed, contact a Poison Control Center right away. Unused or expired drops should be disposed of in accordance with the specific instructions found in the product labeling or by following general guidance for safe medicine disposal.